Toni K Choueiri Selected Research

Sorafenib (BAY 43-9006)

1/2019	Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1.
11/2018	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
9/2017	Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
5/2016	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
11/2013	Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
3/2012	Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
11/2011	Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
11/2011	Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
5/2010	Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
5/2010	Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Toni K Choueiri Research Topics

Disease

294	Renal Cell Carcinoma (Grawitz Tumor) 10/2022 - 12/2003
236	Neoplasms (Cancer) 11/2022 - 08/2004
67	Prostatic Neoplasms (Prostate Cancer) 03/2022 - 03/2006
43	Carcinoma (Carcinomatosis) 03/2022 - 03/2006
37	Neoplasm Metastasis (Metastasis) 01/2022 - 03/2006
31	Kidney Neoplasms (Kidney Cancer) 01/2022 - 08/2007
25	Fatigue 10/2021 - 06/2008
22	Disease Progression 01/2022 - 12/2010
18	Hypertension (High Blood Pressure) 01/2022 - 06/2008
15	Urinary Bladder Neoplasms (Bladder Cancer) 01/2022 - 08/2008
12	Hypoxia (Hypoxemia) 01/2022 - 10/2006
9	Melanoma (Melanoma, Malignant) 01/2022 - 12/2014
7	Breast Neoplasms (Breast Cancer) 05/2014 - 08/2004
6	Adenocarcinoma 03/2022 - 06/2012
6	COVID-19 01/2022 - 01/2020
6	Nausea 01/2021 - 05/2010
6	Exanthema (Rash) 01/2021 - 08/2004
6	Diarrhea 01/2021 - 06/2008
6	Anemia 01/2018 - 11/2011
5	Hematologic Neoplasms (Hematological Malignancy) 03/2022 - 12/2003
5	Brain Neoplasms (Brain Tumor) 12/2021 - 09/2006
5	Heart Failure 09/2015 - 02/2011
4	Margins of Excision 10/2019 - 11/2011
4	Hypothyroidism 01/2018 - 01/2017
4	Pneumonia (Pneumonitis) 01/2017 - 07/2012
4	Hand-Foot Syndrome 05/2016 - 06/2008
4	Transitional Cell Carcinoma 07/2012 - 04/2010
3	Infections 11/2021 - 09/2005
3	Carcinogenesis 01/2021 - 11/2012
3	Obesity 01/2020 - 12/2012

Drug/Important Bio-Agent (IBA)

67	Sunitinib (Sutent)FDA Link 10/2022 - 01/2008
55	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2021 - 10/2006
49	Immune Checkpoint InhibitorsIBA 10/2022 - 11/2015
45	Biomarkers (Surrogate Marker)IBA 11/2022 - 01/2013
32	AndrogensIBA 01/2022 - 03/2009
31	NivolumabIBA 07/2022 - 06/2015
28	Everolimus FDA Link 01/2022 - 05/2011
27	cabozantinibIBA 07/2022 - 11/2015
24	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2008
17	Axitinib (AG 013736)IBA 10/2022 - 06/2008
17	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 10/2022 - 10/2009
17	Pharmaceutical PreparationsIBA 01/2022 - 11/2011
16	PlatinumIBA 03/2022 - 04/2010
16	pazopanib FDA Link 01/2021 - 03/2011
16	Prostate-Specific Antigen (Semenogelase)IBA 01/2020 - 03/2009
14	pembrolizumabIBA 01/2022 - 01/2016
14	IpilimumabIBA 01/2022 - 01/2017
14	DNA (Deoxyribonucleic Acid)IBA 12/2021 - 11/2012
14	Bevacizumab (Avastin)FDA Link 01/2021 - 05/2009
14	Proteins (Proteins, Gene)FDA Link 11/2020 - 03/2006
14	Sorafenib (BAY 43-9006)FDA Link 01/2019 - 01/2008
11	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2014
11	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 05/2007
11	Hemoglobins (Hemoglobin)IBA 01/2018 - 03/2008
10	MTOR InhibitorsIBA 01/2022 - 08/2010
10	B7-H1 AntigenIBA 01/2022 - 07/2014
10	atezolizumabIBA 01/2022 - 01/2018
10	LigandsIBA 11/2020 - 01/2014
9	Biological ProductsIBA 01/2022 - 06/2015
9	TOR Serine-Threonine KinasesIBA 08/2016 - 06/2009
8	avelumabIBA 10/2022 - 01/2018
8	Angiogenesis InhibitorsIBA 05/2014 - 10/2006
7	Messenger RNA (mRNA)IBA 10/2021 - 08/2014
7	Phosphotransferases (Kinase)IBA 10/2018 - 06/2008
6	Monoclonal AntibodiesIBA 01/2021 - 11/2015
6	Formaldehyde (Formol)FDA Link 12/2018 - 07/2014
6	ParaffinIBA 12/2018 - 11/2013
5	Cell-Free Nucleic AcidsIBA 03/2022 - 01/2020
5	Lipase (Acid Lipase)FDA Link 01/2021 - 08/2016
5	temsirolimus FDA Link 01/2020 - 05/2009
5	Docetaxel (Taxotere)FDA Link 01/2018 - 07/2011
5	Hormones (Hormone)IBA 01/2015 - 08/2004
4	lenvatinibIBA 01/2022 - 03/2019
4	Transcription Factors (Transcription Factor)IBA 01/2021 - 10/2009
4	Alanine Transaminase (SGPT)IBA 10/2019 - 08/2013
4	vinflunineIBA 01/2017 - 04/2010
3	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2018
3	abirateroneIBA 01/2022 - 10/2017
3	enzalutamideIBA 01/2022 - 10/2017
3	Circulating Tumor DNAIBA 12/2021 - 10/2017
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2017
3	Amylases FDA Link 10/2019 - 08/2016

Therapy/Procedure

256	Therapeutics 10/2022 - 08/2004
36	Drug Therapy (Chemotherapy) 03/2022 - 03/2006
35	Immunotherapy 11/2022 - 11/2007
27	Nephrectomy 01/2022 - 12/2008
20	Prostatectomy (Retropubic Prostatectomy) 10/2019 - 11/2008
15	Radiotherapy 03/2021 - 08/2008
10	Cystectomy 12/2021 - 08/2008
9	Brachytherapy 01/2019 - 10/2010
7	Castration 03/2022 - 10/2009
7	Neoadjuvant Therapy 12/2021 - 10/2012
6	Metastasectomy 01/2021 - 02/2011
5	Aftercare (After-Treatment) 01/2022 - 02/2011
4	Time-to-Treatment 01/2020 - 08/2010
4	Adjuvant Chemotherapy 02/2018 - 07/2014
4	Salvage Therapy 01/2018 - 04/2010
4	Lymph Node Excision (Lymph Node Dissection) 01/2018 - 05/2007
3	Orchiectomy (Orchidectomy) 11/2021 - 12/2014
3	Duration of Therapy 01/2020 - 09/2012